Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Branched chain amino acids (BCAAs) are a group of essential amino acids—leucine, isoleucine, and valine—that have been studied for their role in supporting liver function, particularly in patients with chronic liver diseases such as hepatitis and cirrhosis. The use of BCAAs in liver disease is primarily supported by scientific research, especially in the context of managing complications such as hepatic encephalopathy (a brain dysfunction caused by liver insufficiency).

Clinical trials and meta-analyses have demonstrated that BCAA supplementation can improve clinical symptoms and quality of life in patients with advanced liver disease. BCAAs help by providing an alternative energy source for muscles and the brain, as the diseased liver is less able to metabolize amino acids effectively. Additionally, BCAAs may help correct the imbalance between aromatic and branched-chain amino acids that occurs in liver disease, which is thought to contribute to neuropsychiatric complications.

However, the evidence supporting BCAA use for the treatment of hepatitis itself (i.e., inflammation of the liver) is less robust. Most studies focus on chronic liver conditions and their complications rather than acute viral hepatitis. The efficacy of BCAAs in improving liver function directly or in halting fibrosis progression is not well established.

In summary, BCAA supplementation is scientifically validated for certain complications of chronic liver disease, particularly hepatic encephalopathy, but its use in treating hepatitis per se is not as strongly supported. The evidence strength is moderate (rated 3/5), mostly for symptomatic management rather than as a curative treatment for hepatitis.

More about branched-chain amino acids
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by branched-chain amino acids

Products containing branched-chain amino acids